Positions
- Professor
-
Breast Center; Department of Molecular & Cellular Biology; Department of Molecular Virology & Microbiology
Baylor College of Medicine
Houston, TX US
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas United States
- Faculty Senator
-
Baylor College of Medicine
Houston, Texas United States
- Member
-
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Addresses
- BCM-Alkek Graduate School (Lab)
-
Room: BCMN-N1220
Houston, TX 77030
United States
- BCM-Alkek Graduate School (Office)
-
Room: BCMN-N1220
Houston, TX 77030
United States
Education
- BS from Jiangsu Agricultural College
- 07/1984 - Yangzhou, Jiangsu China, People's Rep
- MS from Jiangsu Agricultural College
- 07/1987 - Yangzhou, Jiangsu China, People's Rep
- PhD from Michigan State University
- 01/1996 - East Lansing, Michigan United States
- Postdoctoral Training at National Cancer Institute
- 01/2000 - Bethesda, Maryland United States
- Postdoctoral Training at Memorial Sloan Kettering Cancer Center
- 10/2002 - New York, New York United States
Professional Interests
- Breast cancer initiation and progression
- Wnt signaling and cancer stem cells
- Breast Cancer Prevention
- JAK-STAT signaling in breast cancer
Professional Statement
Dr. Yi Li studies breast cancer initiation and metastasis. His lab pioneered an intraductal retroviral mouse model (RCAS/TVA) to closely recapitulate human breast tumorigenesis, identified a mammary progenitor cell population (cytokeratin 6+) and its contribution to breast cancer heterogeneity, discovered a molecular mechanism underlying the dichotomous effects of pregnancy on breast tumorigenesis, and established intermittent anti-STAT5 treatment for preventing breast cancer in preclinical models, which has resulted in a multi-center window-of-opportunity clinical trial (TBCRC042).Websites
Selected Publications
- Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS and Varmus HE "Induction of ovarian cancer by defined multiple genetic changes in a mouse model system.." Cancer Cell. 2002 Feb;1(1):53-62. Pubmed PMID: 12086888
- Li Y Welm B, Podsypanina K, Huang S, Chamorro M, Zhang X, Rowlands R, Egeblad M, Cowin P, Werb Z, Tan LK, Rosen JM and Varmus HE "Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mouse mammary cancers from early cells in mammary development.." PNAS. 2003 Dec;100(26):15853-15858. Pubmed PMID: 14668450
- Zhang X, Podsypanina K, Huang S, Mohsin SK, Chamness GC, Hatsell S, Cowin P, Schiff R, and Li Y. "Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations." Oncogene. 2005 Jun;24(26):4220-4231. Pubmed PMID: 15824740
- Du Z, Podsypanina K, Huang S, McGrath A, Toneff MJ, Bogoslovskaia E, Zhang X, Moraes RC, Fluck M, Allred DC, Lewis MT, Varmus HE, Li Y. "Introduction of oncogenes into mammary glands in vivo with an avian retroviral vector initiates and promotes carcinogenesis in mouse models." Proc Natl Acad Sci USA. 2006 Nov;103(46):17396-401. Pubmed PMID: 17090666
- Lin T, Meng L, Li Y, Tsai RY. "Tumor-initiating function of nucleostemin-enriched mammary tumor cells.." Cancer Res. 2010 Nov;70(22):9444-52. Pubmed PMID: 21045149
- Jackson JG, Pant V, Li Q, Chang LL, Quintás-Cardama A, Garza D, Tavana O, Yang P, Manshouri T, Li Y, El-Naggar AK, Lozano G. "p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer." Cancer Cell. 2012 Jun;21:793-806. Pubmed PMID: 22698404
- Haricharan S, Hein SM, Dong J, Toneff MJ, Aina OH, Rao PH, Cardiff RD, Li Y. "Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer.." Oncogene. 2013 Dec 9 Pubmed PMID: 24317513
- Hatcher RJ, Dong J, Liu S, Bian G, Contreras A, Wang T, Hilsenbeck SG, Li Y, Zhang P. "Pttg1/securin is required for the branching morphogenesis of the mammary gland and suppresses mammary tumorigenesis.." Proc Natl Acad Sci USA. 2014 Jan;111:1008-13. Pubmed PMID: 24395789
- Haricharan S, Dong J, Hein S, Reddy JP, Du Z, Toneff M, Holloway K, Hilsenbeck SG, Huang S, Atkinson R, Woodward W, Jindal S, Borges VF, Gutierrez C, Zhang H, Schedin PJ, Osborne CK, Tweardy DJ, Li Y. "Mechanism and preclinical prevention of increased breast cancer risk caused by pregnancy." eLIFE. 2013 Dec 31;2:e00996.
- Sinha, V.C., Qin, L. & Li, Y. "A p53/ARF-dependent Anticancer Barrier Activates Senescence and Blocks Tumorigenesis without Impacting Apoptosis." Molecular cancer research. 2014;13:231-8. Pubmed PMID: 25253740
- Choi, S., Chen, Z., Tang, L.H., Fang, Y., Shin, S.J., Panarelli, N.C., Chen, Y.T., Li, Y., Jiang, X. & Du, Y.C "Bcl-xL promotes metastasis independent of its anti-apoptotic activity." Nat Commun. 2016;7:10384. Pubmed PMID: 26785948
- Hein, S.M., Haricharan, S., Johnston, A.N., Toneff, M.J., Reddy, J.P., Dong, J., Bu, W. & Li, Y "Luminal epithelial cells within the mammary gland can produce basal cells upon oncogenic stress." Oncogene. 2016;35:1461-7. Pubmed PMID: 26096929
- Zheng, Z.-Y., Tian, L., Bu, W., Fan, C., Gao, X., Wang, H., Liao, Y.-H., Li, Y., Lewis, M.T., Edwards, D., Zwaka, T.P., Hilsenbeck, S.G., Medina, D., Perou, C.M., Creighton, C.J., Zhang, X.H-F., & Chang, E.C "Wild type N-Ras, overexpressed in basal-like breast cancer, drives tumor formation by inducing IL8 secretion via JAK2 activation." Cell Reports. 2015;12:511. Pubmed PMID: 26166574
- Dong, J., Zhao, W., Shi, A., Toneff, M., Lydon, J., & Li, Y. "The PR status of the originating cell of ER/PR-negative breast cancer." Oncogene. 2016:000. Pubmed PMID: 26640140
- Bu, W., Liu, Z., Jiang, W., Nagi, C., Huang, S., Edwards, D.P., Jo, E., Mo, Q., Creighton, C.J., Hilsenbeck, S.G., Leavitt, A.D., Lewis, M.T., Wong, S.T.C. & Li, Y "Mammary precancerous stem and non-stem cells evolve into cancers of distinct subtypes." Cancer Res. 2018 Oct 31 Pubmed PMID: 30401712
- Johnston, A.N., Bu, W., Hein, S., Garcia, S., Camacho, L., Xue, L., Qin, L., Nagi, C., Hilsenbeck, S.G., Kapali, J., Podsypanina, K., Nangia, J. and Li, Y. "Hyperprolactinemia-inducing antipsychotics increase breast cancer risk by activating JAK-STAT5 in precancerous lesions." Breast Cancer Res. 2018 May 19;20:42. Pubmed PMID: 29778097
Funding
- Novel LGR4 Oncogenic Signaling in Breast Cancer Progression and Metastasis - #R01 CA204926 (02/01/2017 - 01/31/2022) Grant funding from NIH
- ALK and TGF-Beta Resistance in Breast Cancer - #BC142202 (09/30/2015 - 09/29/2018) Grant funding from DOD-CDMRP
- Beyond Apoptosis: Bcl-xL in Breast Cancer Metastasis - #BC151736P1 (09/15/2017 - 09/14/2019) Grant funding from DOD-CDMRP
- The cell of origin of breast cancer metastasis - #R21CA202227 Grant funding from NIH
- Intermittent Ruxolitinib to Target STAT5 Activation for Breast Cancer Prevention - #P50 CA186784 (09/19/2014 - 09/18/2019) Grant funding from NIH-SPORE
- Jak2-Stat5 Pathway Blockade To Prevent Breast Cancer - #IIR12223625 ( Grant funding from Susan G. Komen for the Cure
- Ruxolitinib for Preventing Breast Cancer in Women on Neuroleptics - #R01-CA205594 (02/01/2017 - 01/31/2022) Grant funding from NIH
- LGR4 in Breast Cancer Progression and Therapy - #BC160240P1 (02/15/2017 - 02/14/2020) Grant funding from DOD-CDMRP
Log In to edit your profile
